2415-24-9Relevant articles and documents
10-O-acylated iridoid glucosides from leaves of Premna subscandens
Sudo, Hirokazu,Ide, Toshinori,Otsuka, Hideaki,Hirata, Eiji,Takushi, Anki,Takeda, Yoshio
, p. 1231 - 1236 (1997)
From the 1-butanol-soluble fraction of a methanol extract of leaves of Premna subscandens, collected on Ishigaki Island, Okinawa, ten 10-O-acylated derivatives of catalpol and asystasioside E were isolated. The structures of nine new compounds were elucidated by spectroscopic methods and by chemical conversion.
-
Oshio,H.,Inouye,H.
, p. 133 (1982)
-
Isolation, semi-synthesis, docking-based prediction, and bioassay-based activity ofDolichandrone spathaceairidoids: new catalpol derivatives as glucosidase inhibitors
Phuong Thao, Tran Thi,Bui, Thanh Q.,Quy, Phan Tu,Bao, Nguyen Chi,Van Loc, Tran,Van Chien, Tran,Chi, Nguyen Linh,Van Tuan, Nguyen,Van Sung, Tran,Ai Nhung, Nguyen Thi
, p. 11959 - 11975 (2021)
Dolichandrone spathaceairidoids are promising anti-diabetic inhibitors towards α-glucosidase protein (PDB-) and oligo-1,6-glucosidase protein. Five catalpol iridoids(1,2,10,13,14)were isolated from mangrove plantD. spathacea, and their derivatives (3,4,5,6,7,8,9,11,12,15) were obtained from reduction, acetylation,O-alkylation, acetonisation, or hydrolysation starting from naturally isolated compounds. They were identified by spectral methods such as IR, MS, and 1D and 2D NMR. Their glucosidase-related (inhibitability and physiological compatibility were predicted by molecular docking simulation and prescreened based on Lipinski's rule of five. Experimental α-glucosidase inhibition of1-15was evaluated using enzyme assays. Compounds3,4,5,6, and9are new iridoid derivatives, introduced to the literature for the first time, while all fifteen compounds1-15are studied for molecular docking for the first time. Regarding protein, the five strongest predicted inhibitors assemble in the order2>10>1>9>14. In respect to, the corresponding order is14>2>10>5>1=9. Lipinski's criteria suggest10as the candidate with the most potential for oral administration. Thein vitrobioassay revealed that compound10is the most effective inhibitor with a respective IC50value of 0.05 μM, in the order10>2>14>13>1. The computational and experimental results show good consistency. The study opens an alternative approach for diabetes treatment based on inhibitability of natural and semi-synthesised catalpol iridoid derivatives towards carbohydrate-hydrolases.
Eremosides A-C, new iridoid glucosides from Eremostachys loasifolia
Ali, Bakhat,Mehmood, Rashad,Mughal, Uzma Rasheed,Malik, Abdul,Safder, Muhammad,Hussain, Riaz,Imran, Muhammad,Tareen, Rasool Bakhsh
experimental part, p. 586 - 593 (2012/05/20)
Eremosides A-C (1 - 3), three new iridoid glucosides, were isolated from the AcOEt-soluble fraction of the EtOH extract of the whole plant of Eremostachys loasifolia, along with buddlejoside B (4), 10-O-benzoylcatalpol (5), and pakiside A (6) reported for the first time from this species. The structures of these compounds were elucidated by spectroscopic data including 2D-NMR, FAB-MS, ESI-MS, as well as by acid and basic hydrolyses.
PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY
-
Page/Page column 13, (2008/06/13)
The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extractof Pseudolysimachion genus plantand the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL- 13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.